cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24197274.v1
title: Supplementary Material for: Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022

description: Introduction: Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However, patients with CNS involvement are commonly excluded from clinical trials at an unknown rate. We systematically evaluated exclusion criteria of AML clinical trials based on CNS involvement and determined associations with clinical trial characteristics. Methods: The National Institutes of Health Clinical Trials Registry was searched for interventional adult AML trials between 2012-2022 that were phase I, II, or III and relevant trial characteristics were extracted. Results: 1270 trials were included in the analysis with 790 trials (62.1%) explicitly excluding CNS involvement. There was no significant change in rates of CNS exclusion over the past decade. CNS exclusion was higher in trials that included the non-transplant population compared to trials exclusive to the transplant population (66.9% vs. 43.8%, p&lt;0.01). Non-transplant trials were also more likely to exclude patients with a history of or ambiguous timing of CNS involvement (p&lt;0.01). Phase III trials were associated with more liberal definitions of CNS exclusion (history or ambiguous timing) as compared to phase I and II trials that had higher rates of excluding patients with only active CNS involvement (P&lt;0.01). Conclusion: A majority of AML clinical trials, particularly in the non-transplant setting, exclude patients with CNS involvement. Many of these trials, most notably phase 3 trials, exclude patients not only with active, but any history of CNS involvement. Further research is needed to determine optimal management of these patients in order to increase representation in large clinical trials.
DOI: 10.6084/m9.figshare.24278122.v1
title: Supplementary Material for: Effectiveness of antibiotics for uncomplicated diverticulitis: A retrospective investigation using a nationwide database in Japan

description: Introduction: The efficacy of antibiotics for diverticulitis without abscess or peritonitis (uncomplicated diverticulitis) is controversial. We aimed to investigate the effectiveness of antibiotics for uncomplicated diverticulitis. Methods: We collected admissions data for patients with acute uncomplicated diverticulitis using a nationwide database. We divided eligible admissions into two groups according to antibiotics initiation within 2 days after admission (antibiotic group vs. non-antibiotic group). We conducted propensity score matching and compared the rates of surgery (intestinal resection and stoma creation), in-hospital death, and medical costs between the groups. We also performed multivariate analysis to identify the clinical factors that affect surgery using data before propensity score matching. Results: We enrolled 131,936 admissions; among these, we obtained 6061 pairs after propensity score matching. Rates of both intestinal resection and stoma creation in the antibiotic group were lower than those in the non-antibiotic group (0.61% vs. 3.09%, P &lt; 0.0001 and 0.08% vs. 0.26%, P = 0.027, respectively). Median costs in the antibiotic group were higher than those in the non-antibiotic group (315,820 JPY vs. 300,175 JPY, P &lt; 0.0001, respectively). Multivariate analysis showed that non-initiation of antibiotics within 2 days after admission was a clinical factor that increased the risk of intestinal resection (odds ratio [OR] = 5.19, 95% confidence interval [CI]: 4.38‒6.16, P &lt; 0.0001) and stoma creation (OR = 2.68, 95% CI: 1.53‒4.70, P = 0.0006). Conclusion: Our results indicated that antibiotics for uncomplicated diverticulitis expected moderate to severe disease activity may reduce the risk of intestinal resection and stoma creation. Further investigations are warranted.
DOI: 10.6084/m9.figshare.24146754
title: Supplementary Material for: Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019

description: Background: Chronic kidney disease (CKD) is a serious public health issue worldwide, but the disease burden of CKD caused by different etiologies and changing trends have not been fully examined. Methods: We collected data from Global Burden of Disease Study 2019 (GBD 2019), including incident cases, age-standardized incidence rate (ASIR), disability-adjusted life years (DALYs), and age-standardized DALY rate between 1990 and 2019 by region, etiology, age, and sex, and calculated the estimated annual percentage change (EAPC) of the rate to evaluate the epidemiological trends. Results: Globally, incident cases of CKD increased from 7.80 million in 1990 to 18.99 million in 2019, and DALYs increased from 21.50 million to 41.54 million. ASIR increased with an EAPC of 0.69 (95% UI 0.49-0.89) and reached 233.65 per 100,000 in 2019, while the age-standardized DALY rate increased with an EAPC of 0.30 (95% UI 0.17-0.43) and reached 514.86 per 100,000. North Africa and Middle East, central Latin America and North America had the highest ASIR in 2019. Central Latin America had the highest age-standardized DALY rate meanwhile. Almost all countries experienced an increase in ASIR, and over 50% of countries had an increasing trend in age-standardized DALY rate from 1990 to 2019. CKD due to diabetes mellitus type 2 and hypertension accounted for the largest disease burden with 85% incident cases and 66% DALYs in 2019 of known causes, with the highest growth in age-standardized DALY rate and a similar geographic pattern to that of total CKD. Besides, the highest incidence rate of total and four specific CKDs were identified in people aged 70-plus years, who also had the highest DALY rate with a stable trend after 2010. Females had a higher ASIR, while males had a higher age-standardized DALY rate, the gap of which was most distinctive in CKD due to hypertension. Conclusion: The disease burden of CKD remains substantial and continues to grow globally. From 1990 to 2019, global incident cases of CKD have more than doubled and DALYs have almost doubled and surpassed 40 million years. CKD due to diabetes mellitus type 2 and hypertension contribute nearly 2/3 DALYs in 2019 of known causes, and had witnessed the highest growth in age-standardized DALY rate. Etiology-specific prevention strategies should be placed a high priority on the goal of precise control of CKD.
DOI: 10.6084/m9.figshare.24146754.v1
title: Supplementary Material for: Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019

description: Background: Chronic kidney disease (CKD) is a serious public health issue worldwide, but the disease burden of CKD caused by different etiologies and changing trends have not been fully examined. Methods: We collected data from Global Burden of Disease Study 2019 (GBD 2019), including incident cases, age-standardized incidence rate (ASIR), disability-adjusted life years (DALYs), and age-standardized DALY rate between 1990 and 2019 by region, etiology, age, and sex, and calculated the estimated annual percentage change (EAPC) of the rate to evaluate the epidemiological trends. Results: Globally, incident cases of CKD increased from 7.80 million in 1990 to 18.99 million in 2019, and DALYs increased from 21.50 million to 41.54 million. ASIR increased with an EAPC of 0.69 (95% UI 0.49-0.89) and reached 233.65 per 100,000 in 2019, while the age-standardized DALY rate increased with an EAPC of 0.30 (95% UI 0.17-0.43) and reached 514.86 per 100,000. North Africa and Middle East, central Latin America and North America had the highest ASIR in 2019. Central Latin America had the highest age-standardized DALY rate meanwhile. Almost all countries experienced an increase in ASIR, and over 50% of countries had an increasing trend in age-standardized DALY rate from 1990 to 2019. CKD due to diabetes mellitus type 2 and hypertension accounted for the largest disease burden with 85% incident cases and 66% DALYs in 2019 of known causes, with the highest growth in age-standardized DALY rate and a similar geographic pattern to that of total CKD. Besides, the highest incidence rate of total and four specific CKDs were identified in people aged 70-plus years, who also had the highest DALY rate with a stable trend after 2010. Females had a higher ASIR, while males had a higher age-standardized DALY rate, the gap of which was most distinctive in CKD due to hypertension. Conclusion: The disease burden of CKD remains substantial and continues to grow globally. From 1990 to 2019, global incident cases of CKD have more than doubled and DALYs have almost doubled and surpassed 40 million years. CKD due to diabetes mellitus type 2 and hypertension contribute nearly 2/3 DALYs in 2019 of known causes, and had witnessed the highest growth in age-standardized DALY rate. Etiology-specific prevention strategies should be placed a high priority on the goal of precise control of CKD.
DOI: 10.6084/m9.figshare.24125904
title: Supplementary Material for: Proposal of the second cutoff of serum carcinoembryonic antigen levels to stratify patients into low, intermediate, and high risks at recurrences after curative resection of gastric cancer

description: Introduction: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used for various cancers, with the cut-off values of 5.0 ng/mL and 37.0 IU/mL, respectively. However, these cutoff values are not for specific diseases or purposes but are uniformly used for any disease and any purpose . It is also unclear as to whether patients are at equal risk of recurrence if they are below the cutoff values. This study aimed to investigate the optimal cutoff of serum tumor markers in the stratification of recurrence risk after curative resection of gastric cancer. Methods: We constructed a nine-center integrated database of patients recieved gastrectomy between January 2010 and December 2014 with a 5-year follow-up period. We determined the cutoff value of preoperative serum tumor marker levels correlated with postoperative recurrences and evaluated its performance in risk stratification for recurrences in 948 patients with pStage II/III gastric cancer who underwent radical resection. Results: The hazard ratio for postoperative recurrences increased at two points of preoperative CEA levels; 3.6 ng/mL and 5.0 ng/mL, which were set as cutoffs. These two cutoffs stratified relapse-free survival into three levels. Conclusions: By adding a second cutoff value for preoperative serum CEA, which was proposed specifically for the prediction of recurrences, patients can be stratified into low-, intermediate-, and high-risk recurrences after curative resection of gastric cancer.
DOI: 10.6084/m9.figshare.24125904.v1
title: Supplementary Material for: Proposal of the second cutoff of serum carcinoembryonic antigen levels to stratify patients into low, intermediate, and high risks at recurrences after curative resection of gastric cancer

description: Introduction: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used for various cancers, with the cut-off values of 5.0 ng/mL and 37.0 IU/mL, respectively. However, these cutoff values are not for specific diseases or purposes but are uniformly used for any disease and any purpose . It is also unclear as to whether patients are at equal risk of recurrence if they are below the cutoff values. This study aimed to investigate the optimal cutoff of serum tumor markers in the stratification of recurrence risk after curative resection of gastric cancer. Methods: We constructed a nine-center integrated database of patients recieved gastrectomy between January 2010 and December 2014 with a 5-year follow-up period. We determined the cutoff value of preoperative serum tumor marker levels correlated with postoperative recurrences and evaluated its performance in risk stratification for recurrences in 948 patients with pStage II/III gastric cancer who underwent radical resection. Results: The hazard ratio for postoperative recurrences increased at two points of preoperative CEA levels; 3.6 ng/mL and 5.0 ng/mL, which were set as cutoffs. These two cutoffs stratified relapse-free survival into three levels. Conclusions: By adding a second cutoff value for preoperative serum CEA, which was proposed specifically for the prediction of recurrences, patients can be stratified into low-, intermediate-, and high-risk recurrences after curative resection of gastric cancer.
DOI: 10.5517/ccdc.csd.cc2czqbf
title: CCDC 2204265: Experimental Crystal Structure Determination

description: Related Article: Jagadeesan Lakshmipraba, Cheriyan Ebenezer, Rajadurai Vijay Solomon, Muthukumar Venkatesan|2023|Chem.Phys.Imp|7|100286|doi:10.1016/j.chphi.2023.100286
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2d5hlp
title: CCDC 2209822: Experimental Crystal Structure Determination

description: Related Article: Jonathan A. Andrews, Jagadeesh Kalepu, Christopher F. Palmer, Darren L. Poole, Kirsten E. Christensen, Michael C. Willis|2023|J.Am.Chem.Soc.|145|21623|doi:10.1021/jacs.3c07974
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2czqcg
title: CCDC 2204266: Experimental Crystal Structure Determination

description: Related Article: Jagadeesan Lakshmipraba, Cheriyan Ebenezer, Rajadurai Vijay Solomon, Muthukumar Venkatesan|2023|Chem.Phys.Imp|7|100286|doi:10.1016/j.chphi.2023.100286
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5258/soton/d2828
title: Dataset supporting the publication "Textile Solid-State Zinc-ion Capacitor "

description: This dataset supports the publication "Textile Solid-State Zinc-ion Capacitor" presented in E-textile 2023 on 14th – 16th November 2023 | Ghent, Belgium The dataset includes test results for Figure 4 that can be viewed in excel format. The figures are as follows: Figure. 4(a) GC derived Voltage charge and discharge result of the zinc ion capacitor at 25 mA cm-2 tested between 0.1 and 1.8 V, (b) CV tests between 0.1 V to 1.8 V at the scan rate of 10mV.s-1 Related projects: Royal Academy of Engineering under the Chairs in Emerging Technologies Scheme
DOI: 10.5517/ccdc.csd.cc2djlq8
title: CCDC 2220490: Experimental Crystal Structure Determination

description: Related Article: Zhiwei Ma, Yuyuan Wang, Yanyan Liu, Gaoyu Li, Junliang Zhou, Juan Zhao, Zhiyong Yang, Zhenguo Chi|2023|Dyes Pigm.|215|111298|doi:10.1016/j.dyepig.2023.111298
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2djlr9
title: CCDC 2220491: Experimental Crystal Structure Determination

description: Related Article: Zhiwei Ma, Yuyuan Wang, Yanyan Liu, Gaoyu Li, Junliang Zhou, Juan Zhao, Zhiyong Yang, Zhenguo Chi|2023|Dyes Pigm.|215|111298|doi:10.1016/j.dyepig.2023.111298
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2dn80c
title: CCDC 2224002: Experimental Crystal Structure Determination

description: Related Article: Ashlie N. Walker, Megan A. Ayala, Somrita Mondal, Mackenzie C. Bergagnini, Phuong John D. Bui, Stephanie N. Chidester, Chad I. Doeden, Louise Esjornson, Brian R. Sweany, Leslie Garcia, Jeanette A. Krause, Allen G. Oliver, Timothy J. Prior, Timothy J. Hubin|2023|Molecules|28|895|doi:10.3390/molecules28020895
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2dx6bw
title: CCDC 2231638: Experimental Crystal Structure Determination

description: Related Article: Anamika Yadav, Surabhi Upadhyay, Ruchir Kant, Ajay Kumar Srivastava|2023|J.Org.Chem.|88|13568|doi:10.1021/acs.joc.3c01234
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2f17nd
title: CCDC 2235523: Experimental Crystal Structure Determination

description: Related Article: V. Lenin Dandamudi, Payal Malvi|2023|Tetrahedron|145|133603|doi:10.1016/j.tet.2023.133603
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.24160182
title: Supplementary Material for: Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC

description: Background: Biomarkers for predicting the outcome of ipilimumab plus nivolumab (Nivo-Ipi) treatment in cancer patients have not been identified. Herein, we investigated the prognostic significance of inflammatory and nutritional markers in patients with advanced non-small cell lung cancer (NSCLC) receiving Nivo-Ipi. Methods: Our study retrospectively analyzed 101 patients with advanced NSCLC who received Nivo-Ipi at a single institution. Inflammatory and nutritional indices were correlated with patient outcomes and included the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and Glasgow prognostic score (GPS). Results: The NLR significantly correlated with the PLR, SII, PNI, ALI, and GPS. Regarding therapeutic efficacy, the NLR, SII, and PNI predicted a partial response, and all indices predicted progressive disease. In subgroup analyses, the SII, PNI, and ALI predicted the outcome of patients with adenocarcinoma, whereas only the PNI predicted the outcome of patients with non-adenocarcinoma. The PNI and SII were the most useful indices in patients with a programmed death ligand-1 expression level of &lt;1% and ≥1%, respectively. Conclusion: The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.
DOI: 10.6084/m9.figshare.24145386
title: Supplementary Material for: Irisin ameliorated skeletal muscle atrophy by inhibiting fatty acid oxidation and pyroptosis induced by palmitic acid in chronic kidney disease

description: Introduction:Protein-energy waste (PEW) is a common complication in patients with chronic kidney disease (CKD), among which skeletal muscle atrophy is one of the most important clinical features of PEW. Pyroptosis is a type of proinflammatory programmed cell death associated with skeletal muscle disease. Irisin, as a novel myokine, has attracted extensive attention for its protective role in the complications associated with CKD, but its role in muscle atrophy in CKD is unclear.Methods:Palmitic acid (PA) induced muscular atrophy was evaluated by a reduction in C2C12 myotube diameter. Muscle atrophy model was established in male C57BL/6J mice treated with 0.2% adenine for 4 weeks and then fed a 45% high-fat diet.BUN and Cr levels ,body and muscle weight, and muscle histology were assessed. The expression of carnitine palmitoyltransferase 1A (CPT1A) and pyroptosis-related protein was analysed by western blots or immunohistochemistry. The release of IL-1β was detected by ELISA.Results:In this study, we showed that PA induced muscular atrophy and manifested as a reduction in C2C12 myotube diameter. During this process PA can also induce pyroptosis, as shown by the upregulation of NLRP3, cleaved Caspase1 and GSDMD-N expression and the increased IL-1β release and PI-positive cell rate. Inhibition of Caspase1 or NLRP3 attenuated PA-induced pyroptosis and myotube atrophy in C2C12 cells. Importantly, Irisin treatment significantly ameliorated PA-induced skeletal muscle pyroptosis and atrophy. In terms of mechanism, PA upregulated CPT1A, a key enzyme of fatty acid oxidation(FAO), and Irisin attenuated this effect, which was consistent with Etomoxir (CPT1A inhibitor) treatment. Moreover, Irisin improved skeletal muscle atrophy and pyroptosis in adenine-induced mice by regulating FAO. Conclusion: our study firstly verifies that pyroptosis is a novel mechanism of skeletal muscle atrophy in CKD. Irisin ameliorated skeletal muscle atrophy by inhibiting FAO and pyroptosis in CKD, and Irisin may be developed as a potential therapeutic agent for the treatment of muscle wasting in CKD patients.